ArticleMedical oncology (Northwood, London, England)2025
Experimental data supports antineoplastic effects of silkworm protein sericin against colorectal cancer cells.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the 3rd most common cancer in the world. Currently available therapeutic options against CRC hold limited efficacy, substantial side-effects and high costs. Exploring naturally occurring resources to find better options is required to overcome these challenges. Sericin, a naturally occurring protein secreted from silk gland of silkworm "Bombyx mori" is an alternative option in this context. In this study, sericin was extracted from locally available cocoons, while commercially available sericin was purchased for comparison purposes. Multiple bioassays were performed to evaluate the effects of sericin on cancer-related cell processes including proliferation (MTT), colony formation, migration (scratch and invasion), apoptosis (annexin-V and DAPI), cell cycle (FACS) and autophagy (AO/EB) analysis in three human CRC cell lines (SW480, SW620, HCT116). Exposure with extracted and purified sericin fractions induced anti-proliferative effects (up to 40%) in the CRC cells in a time and concentration dependent format. Exposure with low concentration of sericin inhibited migration (13-33%) and colony formation (20-46%) in the CRC cells. Sericin treatment also induced apoptotic effects in the CRC cells as reflected by annexin-V, DAPI and AO/EB staining. Sericin exposure-imposed arrest in S-phase of the cell cycle as measured by propidium iodide-based staining and flow cytometry analysis. Sericin affects vital functional properties of the CRC cells including proliferation, cell cycle, apoptosis, migration and colony formation. Further investigations are needed for the translation of sericin into a therapeutic compound.
Indexed as
Identifiers
41379359What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.